©Reuters.
Axogen, Inc. (NASDAQ:AXGN), a leader in the electronic medical device industry, reported recent transactions involving Angelo Skopelianos, the company's chief research and development officer, according to its latest SEC filings. The report indicates that Skopelinos was involved in both the acquisition and disposal of company stock.
On March 16, 2024, Scopelinos acquired a total of 25,406 shares of Axogen common stock without consideration, reflecting the vesting of restricted stock units. After these transactions, his total ownership in the company increased to his 58,250 shares.
However, on March 21, 2024, Skopelianos sold a total of 6,881 shares of Axogen common stock at a price of $7.68 per share. These sales were made to cover withholding obligations associated with the vesting of restricted stock units and totaled $52,846. Following these sales, Scopelinos' Axogen shareholding decreased to 57,994 shares.
Reported transactions are part of the company's executives' normal financial activities and are disclosed to the public through SEC filings. Investors often monitor these filings for insight into the actions of a company's insiders.
Those interested in tracking Axogen's insider trading activity can track the company's stock on the NASDAQ exchange under the ticker symbol AXGN.
Investment Pro Insights
Given the recent insider trading in Axogen, Inc. (NASDAQ:AXGN), investors may be looking for additional context to understand the company's financial health and market position. According to InvestingPro, the company has a market capitalization of $320.59 million and a price-to-earnings ratio (P/E) of -14.66, reflecting market skepticism about future earnings. The negative PEG ratio of -0.56 further emphasizes this sentiment.
Although the company's revenue growth rate is a solid 14.74% over the past 12 months as of Q4 2023, analysts do not expect Axogen to be profitable this year. Additionally, the company's stock price has fallen significantly over the past month, with the stock's total return being -29.0%. However, it is worth noting that there has been a significant price increase over the past six months. This represents a return of 58.55% over this period, indicating some volatility in stock price performance.
According to InvestingPro Tips, the stock is currently in oversold territory as indicated by the RSI, which could be of interest to potential investors looking for an entry point. It's also important to consider that Axogen operates with moderate debt and has liquid assets in excess of short-term debt, which could provide some financial stability.
For those looking for a more in-depth analysis, InvestingPro offers additional tips on Axogen. For example, two analysts have revised down their earnings forecasts for next year, which could impact future stock performance. To further explore these insights and access more comprehensive research, investors can use a coupon code. pro news 24 Get an extra 10% off your annual or biennial Pro and Pro+ subscriptions and unlock a total of 9 InvestingPro Tips on Axogen.
This article was generated with the help of AI and reviewed by an editor. Please see our Terms of Use for more information.
